Entering text into the input field will update the search result below

APLIF Appili Therapeutics Inc.
Stock Price & Overview

$0.030.0009 (+3.61%)1:21 PM 12/07/23
OTCQB | $USD | Delayed

Charts

FFO (FWD)
PE
Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Ratings Summary

SA Analysts
Wall Street
Quant
Now3M ago6M ago
Valuation
-Rating: Not Covered
Growth
-Rating: Not Covered
Profitability
-Rating: Not Covered
Momentum
-Rating: Not Covered
Revisions
-Rating: Not Covered

See APLIF ratings with Premium.

People Also Follow

Company Profile

Appili Therapeutics Inc. logo
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Employees
9
Founded
2015
Address
  • #21-1344 Summer Street
  • Halifax, NS, B3H 0A8
  • Canada
Phone Number
902-442-4655
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.